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Screening adviceObjectives: To examine the prevalence of drug treatment of bone abnormalities as well as the
clinical determinants of osteoporosis in COPD.
Methods: COPD patients (nZ 554) consecutively entering pulmonary rehabilitation were
included in this cross-sectional study. Medical history, current medication use, smoking status,
lung function, bone mineral density, body composition and other clinical characteristics were
assessed before entering pulmonary rehabilitation.
Univariate- and multivariate multinomial logistic regression analyses were used to deter-
mine correlates of osteoporosis.
Main results: Twenty-one percent of patients had osteoporosis and 41% had osteopenia. Oste-
oporosis was pharmacologically under treated (82% of osteoporotic patients were not receiving
bone medication). Independent predictors of osteoporosis were cachexia (OR: 12.1; 95%CI:
4.5e32.7; p< 0.001), age between 55 and 65 years (OR: 6.0; 95%CI: 2.2e16.3; p< 0.001)
and over 65 years (OR: 11.7; 95%CI: 4.1e33.1; pZ<0.001). Overweight (OR: 0.1; 95%CI:
0.05e0.4; pZ 0.001) and obesity (OR: 0.78; 95%CI: 0.02e0.4; pZ 0.002) showed a substantial
protective effect.
Conclusions: The majority of COPD patients with osteoporosis entering pulmonary rehabilita-
tion did not receive pharmacological treatment for osteoporosis. Cachectic COPD patients
should be screened for osteoporosis, especially when over 55 years of age.
ª 2009 Elsevier Ltd. All rights reserved.Introduction
Chronic obstructive pulmonary disease (COPD) is charac-
terized by a usually progressive airflow limitation that is not
fully reversible according to the Global Strategy for the
Diagnosis, Management, and Prevention of COPD (GOLD).1
COPD comprises a major health burden with an estimated
global prevalence of 9e10% in adults of 40 years and
older.2,3
The GOLD guidelines include ‘‘significant extrapulmo-
nary effects’’ in the definition of COPD,1 indicating that
COPD can be considered a multicomponent disease with
marked extra-pulmonary effects.4e7 Examples of these
effects are loss of muscle mass (with and without abnormal
loss of body weight),8 increased fat mass9 and arterial
stiffness.10 Moreover, COPD patients have a higher risk of
osteoporosis as compared to healthy subjects.11 Indeed,
COPD has been included in the male osteoporosis risk
estimation score.12
Osteoporosis is a systemic skeletal disease characterized
by low bone mineral density (BMD) and microarchitectural
changes in bone tissue that increases the susceptibility to
fractures.13 In patients with established osteoporosis and
patients at high risk of developing osteoporosis (e.g. in case
of oral corticosteroid use of 7.5 mg prednisolone equivalent
a day for at least 6 months), treatment aims at maintaining
BMD and reducing the incidence of osteoporotic frac-
tures.13 In addition to behavioral intervention, treatment
should include bisphosphonates in combination with
calcium supplementation and vitamin D in case of vitamin D
deficiency (‘‘bone medication’’).13
Recent studies have found an abnormal low BMD in COPD
patients entering pulmonary rehabilitation.14e16 Unfortu-
nately, the external and internal validity of these studies is
limited due to small sample sizes and various methodolog-
ical issues. Indeed, the prevalence of pharmacological
treatment of osteoporosis has not been investigated in
COPD patients. Therefore, its prevalence remains currently
unknown. Nevertheless, under diagnosis and, in turn, undertreatment of osteoporosis in these patients in the clinical
routine seems reasonable. Indeed, under treatment of
osteoporosis has been reported in elderly subjects without
airflow limitation and even in patients with fragility frac-
ture.17e20
Previously, the increased prevalence of osteoporosis in
COPD was attributed to the use of oral corticosteroids.21e23
Later, attention was focused on the effects of inhaled
steroids.24e26 Several studies demonstrated that these
drugs have no effect on BMD.27e30 At present, the focus of
investigation is more on factors besides corticosteroids to
explain the increased prevalence of osteoporosis in COPD:
low body mass index (BMI) and low fat free mass index
(FFMI) are known risk factors for osteoporosis in
COPD.14,16,31 None of the aforementioned studies have
taken into account the possible effects of factors such as an
overweight or obese BMI,32 cardiac drug therapies,33e36
serotonin reuptake inhibitors (SSRIs)37 and C-reactive
protein (CRP)38 on the prevalence of osteoporosis in COPD.
Moreover, insight into these factors may help to explain the
underlying mechanisms for the increased risk of osteopo-
rosis in COPD patients.
Given the relative paucity in knowledge about osteopo-
rosis in COPD, the present study aims to examine the
prevalence of drug treatment of osteoporosis and to
determine clinical correlates of osteoporosis and osteope-
nia in COPD patients.Materials and methods
Patient population and study design
COPD patients (nZ 554) consecutively entering pulmonary
rehabilitation were recruited between January 2005 and
April 2007 from the Centre for Integrated Rehabilitation of
Organ Failure (CIRO) in Horn, the Netherlands. All patients
were clinically stable outpatients referred to CIRO by chest
physicians working in respiratory departments of general
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cross-sectional design was used. Diagnosis of COPD was
made according to the ATS guidelines,4 severity classified
according to the GOLD guidelines.1 All assessments were
made before entering a comprehensive pulmonary reha-
bilitation.39 The institutional review board of the University
Hospital of Maastricht approved the study protocol and
written consent was obtained from all study participants.
Clinical characteristics
Medical history, current medication use and smoking status
were assessed by reviewing the medical charts and by
interviewing all patients. Age was divided into three cate-
gories: 55, 56e65 and >65 years.
Forced expiratory volume in the first second (FEV1) and
forced vital capacity (FVC) were assessed using the Jaeger
MASTERLAB BODY (VIASYS Healthcare) and FEV1/FVC was
determined. Arterial blood gases were collected to deter-
mine pH, arterial carbondioxide tension (PaCO2) and arte-
rial oxygen tension (PaO2).
BMIwasdefinedas low(<21 kg/m2),normal (21e25 kg/m2),
overweight (>25e30 kg/m2) and obese (>30 kg/m2). Bio-
impedance analysis was done using the BODYSTAT 1500
medical, single frequency (Xitron Technologies). FFMI was
defined as depleted (men <16 kg/m2 and women <15 kg/m2)
or normal.40 The combination of BMI and FFMI resulted into six
categories: cachexia (low BMI and depleted FFMI), muscle
atrophy (normal BMI and depleted FFMI), semi starvation (low
BMI and normal FFMI), normal (normal BMI and normal
FFMI), overweight (overweight BMI and normal FFMI) and obese
(obese BMI and normal FFMI).8 Whole-body BMD was
determined using a DXA-scan (Lunar Prodigy Ge-Lunar), with
osteoporosis being defined by a T-score <2.35, osteo-
penia: T-score between 2.35 and 0.9, normal BMD:
T-score >0.9.41
CRP was determined in duplicate by high-sensitivity
particle enhanced immunoassay (LABAS micra,
radiometer).
A six-minute walking distance test was conducted twice
on 2 separate days. The longest distance was used in
further analysis.42
Statistical analyses
Discrete variables were compared with the Chi-square test
and presented as percentages. Continuous variables were
compared with ANOVA and presented as means standard
error of mean (SEM).
Univariate- and multivariate-multinomial logistic
regression analyses (enter procedure) were performed to
investigate determinants of osteoporosis and osteopenia in
COPD patients without bone medication. Univariate anal-
yses were used to test for the potentially confounding
effect of biomedical and demographic factors. If significant
at p< 0.05, the variables were included into the multivar-
iate analyses. In addition, several covariates were selected
based on the literature. Specific interactions were tested
within the regression model. A posteriori, specificity of
osteoporosis stratified by the two most important risk
factors for osteoporosis as found in the current study wasdetermined. A p-value <0.05 was used to indicate statis-
tical significance. Odds ratio (OR) with 95% confidence
intervals (CI) are reported. All statistical analyses were
performed using Statistical Package for Social Sciences
(SPSS) version 15.0.Results
Patient characteristics
We included 554 patients with moderate to very severe
COPD. Since only 16 patients (2.9%) were classified as mild
COPD we merged patients with GOLD I and GOLD II into one
category. BMI and/or FFMI were abnormal in 85% of the
patients. The prevalence of osteoporosis was 21%, the
prevalence of osteopenia 41% (Table 1).
Significant differences were found in gender, age, body
composition and functional exercise capacity between
patients with osteoporosis, osteopenia and/or normal BMD
(Table 1).Bone medication
Eighteen percent of the patients used bisphosphonates,
calcium supplementation, vitamin D or a combination
thereof. Surprisingly, patients with osteoporosis were not
using significantly more bone medication as compared to
patients with a normal BMD. Moreover, almost 82% of
patients with osteoporosis were not treated with bone
medication and almost 14% and 23% of patients with
a normal BMD and osteopenia respectively did receive
pharmacological treatment (Table 2). Of patients without
osteoporosis treated with bone medication only 8.1% were
using 7.5 mg prednisolone equivalents a day.Determinants of osteoporosis in patients without
bone medication (nZ 453)
Univariate analysis showed an almost 3-fold increased risk
of osteoporosis in patients between 55 and 65 years as
compared to patients 55, increasing to an OR of 4.5 in
patients over 65 years. To be sure this was not due to an
interaction effect of age and GOLD-stage we repeated the
analyses after stratification for GOLD. Indeed, in all GOLD-
categories age >65 years significantly increased the OR for
osteoporosis. In addition, in GOLD IV patients age between
55 and 65 increased the risk 4-fold (Table 3). Patients
between 55 and 65 years had a 6-fold increased risk of
osteoporosis as compared to patients 55 years, which
even increased to a nearly 12-fold risk in patients over 65
years. Cachectic patients had a 12-fold increased risk of
osteoporosis as compared to patients with a normal body
composition, whereas overweight and obesity showed
a substantial protective effect (Table 4). Specific testing for
interactions within the regression model did not show any
significant results. Cachectic patients over 55 years of age
had an increased risk of osteoporosis as compared to
patients 55 years and/or no cachexia (OR 28.2; 95%CI
10.4e76.9; p< 0.0001).
Table 1 Patients characteristics.
Total group, NZ 554 Normal BMD, NZ 212 Osteopenia, NZ 227 Osteoporosis, NZ 115
Male/Female, % 62/38 60/40 59/41 70/30z
Age, years 65.6 0.4 61.3 0.6 64.5 0.6* 65.8 0.9*
Age 55, % 45 30 19y 11*
Age >55 and 65, % 34 35 31 38
Age >65, % 21 35 50* 51*
FEV1, %pred 42.1 0.7 41.9 1.0 43.6 1.2 39.6 1.5
GOLD Iþ II, % 22 24 23 16
GOLD III, % 34 36 34 30
GOLD IV, % 44 40 43 54y
Smoking
Ex-smoker, % 73 74 75 80
Pack years 39.7 0.8 40.3 1.2 38.9 1.2 40.1 1.6
BMI, kg/m2 24.7 0.2 27.1 0.3 24.3 0.3* 21.2 0.3*x
Low, % 24 9 25* 51*x
Normal, % 33 27 36y 37
High, % 29 41 29y 9*x
Obese, % 14 23 10* 3*z
FFMI
Male, kg/m2 16.9 0.1 17.9 0.2 16.8 0.2* 15.3 0.2*x
Female, kg/m2 14.9 0.1 15.7 0.2 14.7 0.2* 13.7 0.2*x
Low, % 43 24 46* 75*x
Normal, % 57 76 54* 25*x
Body composition
Cachexia, % 23 9 23* 49*x
Muscle atrophy, % 18 13 20y 23y
Semi starvation, % 1 0 2 2
Normal, % 15 14 16 14
Overweight, % 29 41 29y 9*x
Obese, % 14 23 10* 3*z
DXA-scan
BMD, g/cm2 1.081 0.005 1.188 0.005 1.055 0.004* 0.933 0.007*x
T-score 1.29 0.06 0.028 0.05 1.58 0.03 3.26 0.07
CRP 8.4 0.5 8.1 0.7 9.0 1.0 7.5 0.9
6 MWD, m 421.4 5.3 432.5 8.5 419.8 8.4 404.1 11.7
6 MWD, % pred 64.8 0.8 66.0 1.2 65.3 1.2 61.7 1.7y
Values are expressed as mean standard error of mean, unless otherwise indicated. Abbreviations: FEV1Z forced expiratory volume in
the first second, BMIZ body mass index, FFMIZ fat free mass index, BMDZ bone mineral density, CaZ calcium, CRPZ C-reactive
protein, 6 MWDZ six minutes walking distance.
Post hoc tests: *p< 0.01 compared to normal BMD; yp< 0.05 compared to normal BMD; xp< 0.01 compared to osteopenia; zp< 0.05
compared to osteopenia.
1146 L. Graat-Verboom et al.The specificity of not having osteoporosis in low-risk
COPD patients (non-cachectic and age 55) without bone
medication was 91%.
Determinants of osteopenia in patients without
bone medication (nZ 453)
Patients over 65 years of age had a more than 3-fold
increased risk of osteopenia as compared to patients 55
years (Table 5). In addition, cachectic patients had a more
than 3-fold increased risk of osteopenia as compared topatients with a normal body composition, whereas obesity
showed a substantial protective effect of osteopenia.
Discussion
In a large cohort of COPD patients entering pulmonary
rehabilitation the prevalence of osteoporosis was 21% and
of osteopenia 41%. Surprisingly, the majority of the osteo-
porotic patients was not treated with bone medication
(82%). Older patients had an increased risk of osteoporosis
as compared to younger patients. Additionally, cachectic
Table 2 Medication use.
Total group, NZ 554 Normal BMD, NZ 212 Osteopenia, NZ 227 Osteoporosis, NZ 115
Bone medication, % 18 14 22* 18
Bisphosphonates, % 6 4 9* 5
Calcium, % 3 1 4 2
Vitamin D, % 0 1 0 0
Any Combination, % 9 8 9 11
Corticosteroids
Oral, % 21 19 23 18
Inhalation, % 75 77 73 77
Beta mimetics (inh), % 72 72 70 74
Anticholinergics (inh), % 89 90 89 89
Diuretics
Thiazide, % 9 11 8 6
Loop, % 19 21 18 16
Kþ saving, % 4 3 5 3
Statins 19 19 20 15
b-blockers, % 12 12 12 8
SSRIs, % 9 12 8 5*
Values are expressed as percentage of patients using medication. Abbreviations: InhZ inhaled; KþZ potassium; SSRIsZ selective
serotonin reuptake inhibitors. Post hoc tests: *p< 0.005 compared to normal BMD.
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overweight and obese COPD patients had a decreased risk
of osteoporosis as compared to their normal weight peers.
This risk increased even more in cachectic patients >55
years of age irrespective of the severity of COPD. In low-risk
patients (non-cachectic and age 55) only a very small
percentage of osteoporosis (9%) will be missed when not
referred for a DXA-scan.Table 3 Age effects on osteoporosis after stratification
for GOLD-stage.
N OR 95%CI p-value
GOLD I and II 114
<55 yearsa 27
55e65 years 31 2.353 0.398e13.900 .345
>65 years 56 5.500 1.047e28.879 .044
GOLD III 166
<55 yearsa 38
55e65 years 57 2.173 0.514e9.183 .291
>65 years 71 5.739 1.481e22.245 .011
GOLD IV 173
<55 yearsa 37
55e65 years 59 3.789 1.173e12.247 .026
>65 years 77 3.168 1.009e9.951 .048
Total group 453
<55 yearsa 102
55e65 years 147 2.933 1.326e6.488 .008
>65 years 205 4.463 2.073e9.608 <.0001
Analysis was done in patients without bone medication.
a Reference category.Prevalence
The prevalence of osteoporosis of 21% in this study is in line
with previous studies. In brief, prevalence of osteoporosis is
higher in COPD patients as compared to healthy subjects
(24e32% in COPD versus 0e13% in healthy subjects).10,14,43
Moreover, in COPD patients entering pulmonary rehabili-
tation a prevalence of osteoporosis of about 23% was
found.14 In the latter study DXA of the hip and lumbar spine
was used whereas we used whole-body DXA-scan. However,
this difference in methodology was corrected for by
defining osteoporosis according to Boyanov in order to have
a good sensitivity-to-specificity ratio in the diagnosis of
osteoporosis.41 Prevalence of osteoporosis of the current
study differed from two other studies investigating COPD
patients starting pulmonary rehabilitation.15,16 Vrieze and
colleagues found a prevalence ranging from 0% to 18%,
however they used quantitative ultrasound, which is not
the gold standard to measure BMD, and in addition, is hard
to compare to studies using DXA-scanning.16 Engelen and
colleagues used Z-scores, instead of T-scores as recom-
mended by the WHO.13 They found 36% of patients with a Z-
score of <2, and 56% with a Z-score of <1.15
Pharmacological treatment
This is the first study to determine proportion of osteopo-
rotic COPD patients who were treated with bone medica-
tion. In fact, most studies a priori excluded patients using
bone medication15,31,44 or did not report on the prevalence
of bone medication.14,16,45 In the present study, a majority
of COPD patients with osteoporosis were not treated with
bone medication, indicating that these patients were not
recognized as osteoporotic patients by the referring chest
physicians. In the elderly, a high prevalence of under
Table 5 Correlates of osteopenia in patients without
bone medication (results of multivariate analysis)
(nZ 453).
N OR 95%CI p-value
Male 290 1.080 0.636e1.836 .775
Age
<55 yearsa 102
55e65 years 147 1.694 0.886e3.238 .111
>65 years 204 3.398 1.695e6.811 .001y
GOLD I and IIa 114
GOLD III 166 0.938 0.518e1.696 .831
GOLD IV 173 1.127 0.578e2.199 .725
Pack years 453 0.991 0.978e1.004 .175
Body composition
Normala 69
Cachexia 109 3.247 1.392e7.572 .006y
Muscle atrophy 81 1.321 0.609e2.862 .481
Semi starvation 6 2.852 0.264e30.842 .388
Overweight 127 0.522 0.266e1.024 .059
Obese 61 0.364 0.158e0.842 .018y
hs-CRP 453 0.995 0.976e1.015 .631
6 MWD 452 0.999 0.997e1.002 .539
Corticosteroids
Oral 59 1.065 0.520e2.180 .863
Inhaled 337 0.915 0.540e1.552 .742
Diuretics 110 0.691 0.382e1.251 .222
Statins 83 1.162 0.633e2.134 .629
b-blocking agents 53 1.044 0.503e2.166 .908
SSRIs 39 0.780 0.338e1.800 .560
y p-value< 0.05.
Abbreviations: COPDZ chronic obstructive pulmonary disease,
hs-CRPZ high-sensitivity C-reactive protein, 6 MWDZ six
minutes walking distance, SSRIsZ selective serotonin reuptake
inhibitors.
a Reference category.
Table 4 Correlates of osteoporosis in patients without
bone medication (results of multivariate analysis)
(nZ 453).
N OR 95%CI p-value
Male 290 1.732 0.850e3.529 .130
Age
<55 yearsa 102
55e65 years 147 6.020 2.226e16.281 <.0001y
>65 years 204 11.703 4.140e33.082 <.0001y
GOLD I and IIa 114
GOLD III 166 1.086 0.464e2.542 .850
GOLD IV 173 1.864 0.738e4.707 .188
Pack years 453 0.992 0.973e1.011 .393
Body composition
Normala 69
Cachexia 109 12.088 4.469e32.697 <.0001y
Muscle atrophy 81 2.112 0.808e5.524 .127
Semi starvation 6 5.399 0.406e71.874 .202
Overweight 127 0.145 0.047e0.440 0.001y
Obese 61 0.078 0.015e0.399 0.002y
hs-CRP 453 0.979 0.952e1.008 .148
6 MWD 452 0.999 0.996e1.002 .388
Corticosteroids
Oral 59 0.901 0.331e2.457 .839
Inhaled 337 1.133 0.553e2.320 .732
Diuretics 110 1.410 0.618e3.217 .414
Statins 83 0.609 0.252e1.473 .271
b-blocking agents 53 0.784 0.264e2.329 .661
SSRIs 39 0.746 0.215e2.584 .644
y p-value< 0.05.
Abbreviations: COPDZ chronic obstructive pulmonary disease,
hs-CRPZ high-sensitivity C-reactive protein, 6 MWDZ six
minutes walking distance, SSRIsZ selective serotonin reuptake
inhibitors.
a Reference category.
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59 and 91%.20,46 Additionally, screening for and/or treat-
ment of osteoporosis is low in men,18 and even in patients
with fragility fractures diagnosis and/or treatment is often
inadequate.17,19 Therefore, under diagnosis and under
treatment of osteoporosis seem to be a general health
problem rather than a COPD-related issue.
More than 18% of 439 COPD patients without osteopo-
rosis were treated with bone medication. A possible
explanation could be that these patients with former
osteoporosis were successfully treated with bone medica-
tion and continued their treatment. Another explanation
could be daily use of oral corticosteroids for at least 6
months with 7.5 mg prednisolone equivalents a day or
more, since the WHO advises to treat these patients with
bone medication.13 In the current study, only 8.1% of 80
patients without osteoporosis treated with bone medica-
tion used 7.5 mg prednisolone. Since osteonecrosis of the
jaw is one of the potential side effects of treatment with
bisphosphonates47,48 we recommend a DXA-scan to confirm
diagnosis of osteoporosis before starting treatment withbone medication. In addition, we had no information on
previous fragility fractures in the patients or their parents,
therefore we do not know whether or not these patients
met criteria for treatment based on the WHO FRAX 10-year
fracture risk calculator.49
Correlates of osteopenia
No previous studies have focused on risk factors for osteo-
penia in COPD. We found age >65 years and cachexia to be
independent correlates. In addition, obesity was protective
of osteopenia. More longitudinal studies are needed inves-
tigating potential risk factors for osteopenia in order to
identify these patients and perform regular DXA-scanning in
order to detect progression to osteoporosis in an early stage.
Correlates of osteoporosis
The WHO indicates that the onset of substantial bone loss
starts at 65 years in men and 50 years in women.13 In the
present study, patients between 55 and 65 years had
Correlates of osteoporosis in COPD 1149a 6-fold increased risk of osteoporosis compared to younger
peers, which even increased to a more than 11-fold risk in
patients over 65 years. This is the first study to find age to
be a significant, independent risk factor for osteoporosis in
COPD. In addition, cachectic patients had an increased risk
of osteoporosis. This is in line with other studies.16,31,44,50
In the current study we combined FFMI with BMI in order to
make a more precise risk estimation of osteoporosis in
COPD patients. Indeed, Bolton and colleagues found the
highest prevalence of osteoporosis (50%) and osteopenia
(50%) in cachectic COPD patients.14 Unfortunately, they did
not investigate the influence of overweight or obesity on
osteoporosis. In the present study, overweight and obese
COPD patients had a decreased risk of osteoporosis, as
compared to normal weight peers. At first this finding
seems somewhat surprising, since obesity has been linked
to an increased production of inflammatory cytokines which
may impair bone formation.51 However, an increased daily
physiological mechanical loading of the cortical skeleton
may prevent an abnormal loss of BMD in obese subject.52
No previous study investigated the combined effect of
age and body composition on BMD in COPD patients. In the
present study the combination of cachexia and age >55
increased the risk of osteoporosis even more than either of
the two variables separately.
Female gender was not a significant risk factor for
osteoporosis although in the overall population women are
at increased risk of osteoporosis as compared to their male
peers.13 This may in part be explained by the fact that
female patients were significantly younger than male
patients (mean age: 59 versus 66 years). In addition we did
not find an independent effect of CRP, cardiac medication
and SSRIs on osteoporosis in the present sample. There are
no studies in COPD patients that included the previously
mentioned covariates in their analyses. However, in
patients without COPD, circulating levels of high-sensitivity
CRP (hs-CRP) were found to be significantly higher in
healthy women with the lowest BMD.38 Possibly, this higher
hs-CRP was not found in COPD patients with osteoporosis
since hs-CRP levels are already elevated as compared to
healthy subjects due to chronic low-grade systemic
inflammation in COPD. In addition, thiazide diuretics, beta-
blocking agents and statins decrease the risk of osteo-
porosis,33e36 whereas SSRIs37 increase this risk in subjects
without COPD. We found no significant influence of corti-
costeroids on osteoporosis. This could be due to the fact
that we corrected for several other covariates including
degree of airflow obstruction. Indeed, de Vries and
colleagues found the influence of inhaled corticosteroids to
disappear after correcting for airflow obstruction.27 In
addition, the duration of treatment with oral corticoste-
roids, the number of courses and the cumulative dose were
unknown, and different corticosteroid regimens had
different effects on BMD.21 Further (longitudinal) research
regarding these potential confounders of osteoporosis in
COPD patients is needed.
Clinical considerations
In the integrated care of COPD patients the importance of
recognizing and treating extrapulmonary features is
stressed.1,53 Based on the present results, it seemsreasonable to conclude that the awareness regarding
diagnosis and/or pharmacological treatment of osteopo-
rosis in COPD patients entering pulmonary rehabilitation is
rather low amongst referring chest physicians. An extensive
phenotyping of complex and (mostly) extra-pulmonary
features in COPD patients entering pulmonary rehabilita-
tion seems necessary.39 Recently, Shepherd and colleagues
advised to screen for osteoporosis in men with COPD over
55 years of age and/or having a body weight <80 kg.12
Based on the current results, we would advise chest
physicians to screen for osteoporosis in cachectic COPD
patients older than 55 years, irrespective of gender or
GOLD classification.
Methodological considerations
Some limitations of the current study should be noted.
First, the external validity may be limited to COPD patients
entering pulmonary rehabilitation. However, a comparable
prevalence of osteoporosis has been found in COPD patients
in primary care settings as well as in outpatients.43,45
Whether or not COPD patients entering rehabilitation are
representative for the whole population remains currently
unknown. At least the patients starting pulmonary reha-
bilitation form a representative sample of COPD patients
referred to chest physicians. The included patients repre-
sent different stages of COPD severity as reflected by the
GOLD stages. Second, a control group was lacking. Never-
theless, previous studies did already find an increased
prevalence of osteoporosis as compared to healthy
subjects.11 The third limitation is that we did not have
information on duration of treatment with oral corticoste-
roids and treatment courses in the past. However, no
differences were found in prevalence of patients on main-
tenance oral corticosteroids between normal BMD, osteo-
penia and osteoporosis (Table 2). Moreover, not all current
oral steroid users had osteoporosis and not all osteoporotic
patients used oral steroids at the time of the study.
Therefore, it seems reasonable to conclude that oral
steroid use may partially explain the presence of osteopo-
rosis in patients with COPD. Then again, the pathophysi-
ology of osteoporosis in COPD is clearly multi-factorial.
Another limitation is that we did not gather information
about previous fractures in patients and their parents;
important known risk factors in the general population for
fractures and incorporated in the FRAX fracture calculation
tool of the WHO.49 However, the aim of the study was not to
estimate 10-year fracture risk but to investigate preva-
lence, prevalence of treatment and correlates of osteopo-
rosis as defined by DXA. More studies are needed
investigating this 10-year fracture risk in COPD patients. On
the other hand, more research has to be done to investigate
whether or not COPD in itself should be incorporated in the
FRAX scoring system like rheumatoid arthritis. Indeed, in
the male osteoporosis risk estimation score COPD was
included as a risk factor.12 Furthermore, we did not
measure daily physical (in)activity in COPD. We did use the
6 min walking distance in our analyses which can be used as
a surrogate marker of daily physical activity, particularly in
COPD patients with a walking distance of about 400 m.42
Finally, we used whole-body DXA instead of DXA at lumbar
spine or hip and the diagnosis of osteoporosis according to
1150 L. Graat-Verboom et al.the WHO is based on T-scores measured at the hip or lumbar
spine.13 Therefore, we used recently determined cut-off
values by Boyanov in order to have a good sensitivity-to-
specificity ratio in the diagnosis of lumbar spine osteopo-
rosis and low bone mass.41
In conclusion, more than 1 out of every 5 COPD patients
entering pulmonary rehabilitation have osteoporosis.
However, most of these osteoporotic COPD patients do not
receive WHO-advised treatment to prevent fractures.
Higher age and cachexia increase the risk of osteoporosis in
COPD patients, irrespective of other clinically relevant
factors. In contrast, overweight and obese COPD patients
have a decreased risk of osteoporosis. Based on our findings
we advise chest physicians to refer cachectic COPD
patients for a DXA-scan, especially when they are older
than 55 years of age irrespective of gender or COPD
severity.
Conflicts of interest
All authors have no conflicts of interests.Acknowledgements
This project was supported by: Centre for Integrated
Rehabilitation of Organ failure (CIRO) Horn, the
Netherlands.
References
1. Rabe KF, Hurd S, Anzueto A, et al. Global strategy for the
diagnosis, management, and prevention of chronic obstructive
pulmonary disease: GOLD executive summary. Am J Respir Crit
Care Med 2007;176:532e55.
2. Murray CJ, Lopez AD. Global mortality, disability, and the
contribution of risk factors: Global Burden of Disease Study.
Lancet 1997;349:1436e42.
3. Lopez AD, Mathers CD, Ezzati M, Jamison DT, Murray CJ. Global
and regional burden of disease and risk factors, 2001:
systematic analysis of population health data. Lancet 2006;
367:1747e57.
4. Standards for the diagnosis and care of patients with chronic
obstructive pulmonary disease. American Thoracic Society. Am
J Respir Crit Care Med 1995;152:S77e121.
5. Agusti AG. Systemic effects of chronic obstructive pulmonary
disease. Proc Am Thorac Soc 2005;2:367e70.
6. Andreassen H, Vestbo J. Chronic obstructive pulmonary disease
as a systemic disease: an epidemiological perspective. Eur
Respir J Suppl 2003;46:2se4s.
7. Wouters EF. Introduction: systemic effects in chronic obstruc-
tive pulmonary disease. Eur Respir J Suppl 2003;46:1s.
8. Schols AM, Broekhuizen R, Weling-Scheepers CA, Wouters EF.
Body composition and mortality in chronic obstructive pulmo-
nary disease. Am J Clin Nutr 2005;82:53e9.
9. Vestbo J, Prescott E, Almdal T, et al. Body mass, fat-free body
mass, and prognosis in patients with chronic obstructive
pulmonary disease from a random population sample: findings
from the Copenhagen City Heart Study. Am J Respir Crit Care
Med 2006;173:79e83.
10. Sabit R, Bolton CE, Edwards PH, et al. Arterial stiffness and
osteoporosis in chronic obstructive pulmonary disease. Am J
Respir Crit Care Med 2007;175:1259e65.11. Graat-Verboom L, Wouters EF, Smeenk FW, Borne van den BE,
Lunde R, Spruit MA. Current status of research on osteoporosis
in COPD: a systematic review. Eur Respir J, in press.
12. Shepherd AJ, Cass AR, Carlson CA, Ray L. Development and
internal validation of the male osteoporosis risk estimation
score. Ann Fam Med 2007;5:540e6.
13. WHO Scientific Group on the Prevention and Management of
Osteoporosis. Prevention and management of osteoporosis:
report of a WHO scientific group [WHO technical report series;
921], http://whqlibdoc who int/trs/WHO_TRS_921 pdf; 2007.
14. Bolton CE, Ionescu AA, Shiels KM, et al. Associated loss of fat-free
mass and bone mineral density in chronic obstructive pulmonary
disease. Am J Respir Crit Care Med 2004;170:1286e93.
15. Engelen MP, Schols AM, Heidendal GA, Wouters EF. Dual-energy
X-ray absorptiometry in the clinical evaluation of body
composition and bone mineral density in patients with chronic
obstructive pulmonary disease. Am J Clin Nutr 1998;68:
1298e303.
16. Vrieze A, de Greef MH, Wijkstra PJ, Wempe JB. Low bone
mineral density in COPD patients related to worse lung func-
tion, low weight and decreased fat-free mass. Osteoporos Int
2007;18:1197e202.
17. Freedman BA, Potter BK, Nesti LJ, Cho T, Kuklo TR. Missed
opportunities in patients with osteoporosis and distal radius
fractures. Clin Orthop Relat Res 2007;454:202e6.
18. Gruntmanis U. Male osteoporosis: deadly, but ignored. Am J
Med Sci 2007;333:85e92.
19. Hajcsar EE, Hawker G, Bogoch ER. Investigation and treatment
of osteoporosis in patients with fragility fractures. CMAJ 2000;
163:819e22.
20. Wright RM. Use of osteoporosis medications in older nursing
facility residents. J Am Med Dir Assoc 2007;8:453e7.
21. Dubois EF, Roder E, Dekhuijzen PN, Zwinderman AE,
Schweitzer DH. Dual energy X-ray absorptiometry outcomes in
male COPD patients after treatment with different glucocor-
ticoid regimens. Chest 2002;121:1456e63.
22. Gluck O, Colice G. Recognizing and treating glucocorticoid-
induced osteoporosis in patients with pulmonary diseases.
Chest 2004;125:1859e76.
23. Goldstein MF, Fallon Jr JJ, Harning R. Chronic glucocorticoid
therapy-induced osteoporosis in patients with obstructive lung
disease. Chest 1999;116:1733e49.
24. Effect of inhaled triamcinolone on the decline in pulmonary
function in chronic obstructive pulmonary disease. N Engl J
Med 2000;343:1902e9.
25. Israel E, Banerjee TR, Fitzmaurice GM, Kotlov TV, LaHive K,
LeBoff MS. Effects of inhaled glucocorticoids on bone density in
premenopausal women. N Engl J Med 2001;345:941e7.
26. Wong CA, Walsh LJ, Smith CJ, et al. Inhaled corticosteroid use
and bone-mineral density in patients with asthma. Lancet
2000;355:1399e403.
27. de Vries F, van Staa TP, Bracke MS, Cooper C, Leufkens HG,
Lammers JW. Severity of obstructive airway disease and risk of
osteoporotic fracture. Eur Respir J 2005;25:879e84.
28. Elmstahl S, Ekstrom H, Galvard H, Johnell O, Gerhardsson DV,
Norjavaara E. Is there an association between inhaled corti-
costeroids and bone density in postmenopausal women?
J Allergy Clin Immunol 2003;111:91e6.
29. Li JT, Ford LB, Chervinsky P, et al. Fluticasone propionate
powder and lack of clinically significant effects on hypotha-
lamic-pituitary-adrenal axis and bone mineral density over 2
years in adults with mild asthma. J Allergy Clin Immunol 1999;
103:1062e8.
30. Pauwels RA, Lofdahl CG, Laitinen LA, et al. Long-term treat-
ment with inhaled budesonide in persons with mild chronic
obstructive pulmonary disease who continue smoking. Euro-
pean Respiratory Society Study on Chronic Obstructive
Pulmonary Disease. N Engl J Med 1999;340:1948e53.
Correlates of osteoporosis in COPD 115131. Incalzi RA, Caradonna P, Ranieri P, et al. Correlates of osteo-
porosis in chronic obstructive pulmonary disease. Respir Med
2000;94:1079e84.
32. Looker AC, Flegal KM, Melton III LJ. Impact of increased
overweight on the projected prevalence of osteoporosis in
older women. Osteoporos Int 2007;18:307e13.
33. Bonnet N, Gadois C, McCloskey E, et al. Protective effect of aˆ
blockers in postmenopausal women: influence on fracures, bone
density, micro and macroarchitecture. Bone 2007;40:1209e16.
34. Pasco JA, Henry MJ, Sanders KM, Kotowicz MA, Seeman E,
Nicholson GC. Beta-adrenergic blockers reduce the risk of
fracture partly by increasing bone mineral density: Geelong
Osteoporosis Study. J Bone Miner Res 2004;19:19e24.
35. Schoofs MW, van der Klift M, Hofman A, et al. Thiazide
diuretics and the risk for hip fracture. Ann Intern Med 2003;
139:476e82.
36. Schoofs MW, Sturkenboom MC, van der KM, Hofman A, Pols HA,
Stricker BH. HMG-CoA reductase inhibitors and the risk of
vertebral fracture. J Bone Miner Res 2004;19:1525e30.
37. Haney EM, Chan BK, Diem SJ, et al. Association of low bone
mineral density with selective serotonin reuptake inhibitor use
by older men. Arch Intern Med 2007;167:1246e51.
38. Koh JM, Khang YH, Jung CH, et al. Higher circulating hsCRP
levels are associated with lower bone mineral density in
healthy pre- and postmenopausal women: evidence for a link
between systemic inflammation and osteoporosis. Osteoporos
Int 2005;16:1263e71.
39. Spruit MA, Vanderhoven-Augustin I, Janssen PP, Wouters EF.
Integration of pulmonary rehabilitation in COPD. Lancet 2008;
371:12e3.
40. Baarends EM, Schols AM, Mostert R, Wouters EF. Peak exercise
response in relation to tissue depletion in patients with chronic
obstructive pulmonary disease. Eur Respir J 1997;10:2807e13.
41. Boyanov M. Estimation of lumbar spine bone mineral density by
dual-energy X-ray absorptiometry: standard anteroposterior
scans vs sub-regional analyses of whole-body scans. Br J Radiol
2008;81:637e42.
42. Pitta F, Troosters T, Spruit MA, Probst VS, Decramer M,
Gosselink R. Characteristics of physical activities in daily life inchronic obstructive pulmonary disease. Am J Respir Crit Care
Med 2005;171:972e7.
43. Dimai HP, Domej W, Leb G, Lau KH. Bone loss in patients with
untreated chronic obstructive pulmonary disease is mediated
by an increase in bone resorption associated with hypercapnia.
J Bone Miner Res 2001;16:2132e41.
44. Iqbal F, Michaelson J, Thaler L, Rubin J, Roman J, Nanes MS.
Declining bone mass in men with chronic pulmonary disease:
contribution of glucocorticoid treatment, body mass index,
and gonadal function. Chest 1999;116:1616e24.
45. Sin DD, Man JP, Man SF. The risk of osteoporosis in Caucasian
men and women with obstructive airways disease. Am J Med
2003;114:10e4.
46. Vik SA, Jantzi M, Poss J, et al. Factors associated with phar-
macologic treatment of osteoporosis in an older home care
population. J Gerontol A Biol Sci Med Sci 2007;62:872e8.
47. Pazianas M, Miller P, Blumentals WA, Bernal M, Kothawala P. A
review of the literature on osteonecrosis of the jaw in patients
with osteoporosis treated with oral bisphosphonates: preva-
lence, risk factors, and clinical characteristics. Clin Ther 2007;
29:1548e58.
48. Reid IR, Bolland MJ, Grey AB. Is bisphosphonate-associated
osteonecrosis of the jaw caused by soft tissue toxicity? Bone
2007;41:318e20.
49. Kanis JA, Johnell O, Oden A, Johansson H, McCloskey E. FRAX
and the assessment of fracture probability in men and women
from the UK. Osteoporos Int 2008;19:385e97.
50. Engelen MP, Schols AM, Lamers RJ, Wouters EF. Different
patterns of chronic tissue wasting among patients with chronic
obstructive pulmonary disease. Clin Nutr 1999;18:275e80.
51. Weisberg SP, McCann D, Desai M, Rosenbaum M, Leibel RL,
Ferrante Jr AW. Obesity is associated with macrophage
accumulation in adipose tissue. J Clin Invest 2003;112:
1796e808.
52. Reid IR. Obesity and osteoporosis. Ann Endocrinol (Paris) 2006;
67:125e9.
53. Nici L, Donner C, Wouters E, et al. American Thoracic Soci-
ety/European Respiratory Society statement on pulmonary
rehabilitation. Am J Respir Crit Care Med 2006;173:1390e413.
